NYSE:JNJPharmaceuticals
Does J&J’s MONARCH QUEST 3 Approval and MedTech Momentum Change The Bull Case For Johnson & Johnson (JNJ)?
In recent days, Johnson & Johnson reported past quarterly operational sales growth led by its Innovative Medicine and MedTech businesses and raised its full-year outlook while securing U.S. 510(k) and FDA clearances for the MONARCH QUEST 3 AI-enabled bronchoscopy software update.
Taken together, stronger operating performance and regulatory progress in robotic lung procedures underscore how Johnson & Johnson is leaning on innovation across medicines and devices to reinforce its diversified...